Literature DB >> 22308372

Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal.

Taryn E Grieder1, Olivier George, Huibing Tan, Susan R George, Bernard Le Foll, Steven R Laviolette, Derek van der Kooy.   

Abstract

Nicotine, the main psychoactive ingredient of tobacco smoke, induces negative motivational symptoms during withdrawal that contribute to relapse in dependent individuals. The neurobiological mechanisms underlying how the brain signals nicotine withdrawal remain poorly understood. Using electrophysiological, genetic, pharmacological, and behavioral methods, we demonstrate that tonic but not phasic activity is reduced during nicotine withdrawal in ventral tegmental area dopamine (DA) neurons, and that this pattern of signaling acts through DA D2 and adenosine A2A, but not DA D1, receptors. Selective blockade of phasic DA activity prevents the expression of conditioned place aversions to a single injection of nicotine in nondependent mice, but not to withdrawal from chronic nicotine in dependent mice, suggesting a shift from phasic to tonic dopaminergic mediation of the conditioned motivational response in nicotine dependent and withdrawn animals. Either increasing or decreasing activity at D2 or A2A receptors prevents the aversive motivational response to withdrawal from chronic nicotine, but not to acute nicotine. Modification of D1 receptor activity prevents the aversive response to acute nicotine, but not to nicotine withdrawal. This double dissociation demonstrates that the specific pattern of tonic DA activity at D2 receptors is a key mechanism in signaling the motivational effects experienced during nicotine withdrawal, and may represent a unique target for therapeutic treatments for nicotine addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308372      PMCID: PMC3286981          DOI: 10.1073/pnas.1114422109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Annual smoking-attributable mortality, years of potential life lost, and economic costs--United States, 1995-1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-04-12       Impact factor: 17.586

Review 2.  The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving.

Authors:  A A Grace
Journal:  Addiction       Date:  2000-08       Impact factor: 6.526

3.  Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes.

Authors:  Steven R Laviolette; Karim Nader; Derek van der Kooy
Journal:  Behav Brain Res       Date:  2002-02-01       Impact factor: 3.332

4.  Identification of a dopamine receptor-mediated opiate reward memory switch in the basolateral amygdala-nucleus accumbens circuit.

Authors:  Alessandra Lintas; Ning Chi; Nicole M Lauzon; Stephanie F Bishop; Shervin Gholizadeh; Ninglei Sun; Huibing Tan; Steven R Laviolette
Journal:  J Neurosci       Date:  2011-08-03       Impact factor: 6.167

5.  Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study.

Authors:  J F Cheer; C A Marsden; D A Kendall; R Mason
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

6.  Comparison of interactions of D1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: locomotor activity and drug discrimination studies in rodents.

Authors:  Allison L Chausmer; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2001-09-22       Impact factor: 4.530

7.  Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area.

Authors:  S R Laviolette; D van der Kooy
Journal:  Mol Psychiatry       Date:  2003-01       Impact factor: 15.992

8.  Lesions of the tegmental pedunculopontine nucleus block the rewarding effects and reveal the aversive effects of nicotine in the ventral tegmental area.

Authors:  Steven R Laviolette; Tania O Alexson; Derek van der Kooy
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

9.  SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.

Authors:  C Cohen; G Perrault; C Voltz; R Steinberg; P Soubrié
Journal:  Behav Pharmacol       Date:  2002-09       Impact factor: 2.293

10.  Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area: in vivo microdialysis study.

Authors:  S Rahman; J Zhang; W A Corrigall
Journal:  Neurosci Lett       Date:  2003-09-11       Impact factor: 3.046

View more
  34 in total

1.  Shifting pharmacology of nicotine use and withdrawal: breaking the cycle of drug abuse.

Authors:  Thibaut Sesia; Anthony A Grace
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-03       Impact factor: 11.205

Review 2.  Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.

Authors:  George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2017-01-03       Impact factor: 4.530

Review 3.  The mysterious motivational functions of mesolimbic dopamine.

Authors:  John D Salamone; Mercè Correa
Journal:  Neuron       Date:  2012-11-08       Impact factor: 17.173

4.  Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice.

Authors:  Monica R F Hilario; Jill R Turner; Julie A Blendy
Journal:  Neuropsychopharmacology       Date:  2012-07-25       Impact factor: 7.853

5.  Cognitive Fatigue Effects on Physical Performance: The Role of Interoception.

Authors:  Terry McMorris
Journal:  Sports Med       Date:  2020-10       Impact factor: 11.136

6.  β2* nAChRs on VTA dopamine and GABA neurons separately mediate nicotine aversion and reward.

Authors:  Taryn E Grieder; Morgane Besson; Geith Maal-Bared; Stéphanie Pons; Uwe Maskos; Derek van der Kooy
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-27       Impact factor: 11.205

7.  Behavior of knock-in mice with a cocaine-insensitive dopamine transporter after virogenetic restoration of cocaine sensitivity in the striatum.

Authors:  Brian O'Neill; Michael R Tilley; Dawn D Han; Keerthi Thirtamara-Rajamani; Erik R Hill; Georgia A Bishop; Fu-Ming Zhou; Matthew J During; Howard H Gu
Journal:  Neuropharmacology       Date:  2014-01-09       Impact factor: 5.250

8.  Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study.

Authors:  Rebecca L Ashare; E Paul Wileyto; Kosha Ruparel; Patricia M Goelz; Ryan D Hopson; Jeffrey N Valdez; Ruben C Gur; James Loughead; Caryn Lerman
Journal:  Drug Alcohol Depend       Date:  2013-09-14       Impact factor: 4.492

Review 9.  Glial cells as therapeutic targets for smoking cessation.

Authors:  Mohit Kumar; Adewale Adeluyi; Erin L Anderson; Jill R Turner
Journal:  Neuropharmacology       Date:  2020-05-24       Impact factor: 5.250

Review 10.  The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.

Authors:  James P Burkett; Larry J Young
Journal:  Psychopharmacology (Berl)       Date:  2012-08-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.